AroCell has previously announced that they have signed a distribution agreement with Sub-Saharan Biomedical P.L.C. for the sale of TUBEX TF in Ethiopia.

Over the past few months, AroCell, together with its distributor, has been working on the local regulatory process and has now obtained regulatory approval for TUBEX TF in Ethiopia.

Attaining regulatory approval is a challenging process but provides a competitive advantage once obtained.

After its launch in Africa, AroCell has focused on finding suitable distribution partners. The company has previously announced that it has signed agreements with distributors in Uganda, Ghana, and Kenya among others. These agreements involve the sale of the company's rapid test TUBEX TF for typhoid fever.

'Ethiopia is a large country with 120 million inhabitants and a potentially important market for TUBEX TF. It is gratifying that we have now accomplished the regulatory work,' says Gunnar Wahlberg, Sales Manager for rapid tests at AroCell.

Contact:

Anders Hultman

Tel: +46 (0) 8 799 67 50

Email: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser.

(C) 2024 Electronic News Publishing, source ENP Newswire